| . | 1.9 yr of age . | 5 yr of age . | 6.1 yr of age . | |||
|---|---|---|---|---|---|---|
| Patient . | Reference range . | Patient . | Reference range . | Patient . | Reference range . | |
| Absolute lymphocyte count (G/liter) | 7.4 | 2.7–11.9 | 4.5 | 1.7–6.9 | 3.9 | 1.1–5.9 |
| CD3+ T cells (cells/μl) | 4,600 | 1,400–8,000 | 2,831 | 900–4,500 | 2,876 | 700–4,200 |
| CD3+HLA-DR+ (%) | 6 | 3–13 | 16 | 3–14 | ||
| CD4+ T cells (cells/μl) | 3,030 | 900–5,500 | 1,716 | 500–2,400 | 1,244 | 300–2,000 |
| CD45RA+CCR7+ (%) | 78.5 | 57.4–84.9 | ||||
| CD45RA−CCR7+ (%) | 9.8 | 11.3–26.7 | ||||
| CD45RA−CCR7− (%) | 9.1 | 3.3–15.2 | ||||
| CD45RA+CCR7− (%) | 1.7 | 0.4–2.6 | ||||
| CD8+ T cells (cells/μl) | 1,570 | 400–2,300 | 1,009 | 300–1,600 | 1,459 | 300–1,800 |
| CD45RA+CCR7+ (%) | 44.9 | 28.4–80.6 | ||||
| CD45RA−CCR7+ (%) | 1 | 1–4.5 | ||||
| CD45RA−CCR7− (%) | 6.7 | 6.2–29.3 | ||||
| CD45RA+CCR7− (%) | 43.1 | 9.1–49.1 | ||||
| CD4/CD8 | 1.9 | 1–3 | 1.7 | 1–2.1 | 0.85 | 0.9–2.6 |
| CD56+CD16+ NK cells (cells/μl) | 110 | 61–510 | 99 | 70–590 | 231 | 70–590 |
| CD19+ B cells (cells/μl) | 1,560 | 529–1,930 | 1,532 | 323–1,000 | 788 | 212–796 |
| CD27−IgD+ naive (%) | 96 | 70–86 | 93 | 63–89 | ||
| CD27+IgD+ nonswitched memory (%) | 3 | 7–15 | 3 | 3–19 | ||
| CD27+IgD− class-switched memory (%) | 1 | 4–16 | 3 | 4–17 | ||
| . | 1.9 yr of age . | 5 yr of age . | 6.1 yr of age . | |||
|---|---|---|---|---|---|---|
| Patient . | Reference range . | Patient . | Reference range . | Patient . | Reference range . | |
| Absolute lymphocyte count (G/liter) | 7.4 | 2.7–11.9 | 4.5 | 1.7–6.9 | 3.9 | 1.1–5.9 |
| CD3+ T cells (cells/μl) | 4,600 | 1,400–8,000 | 2,831 | 900–4,500 | 2,876 | 700–4,200 |
| CD3+HLA-DR+ (%) | 6 | 3–13 | 16 | 3–14 | ||
| CD4+ T cells (cells/μl) | 3,030 | 900–5,500 | 1,716 | 500–2,400 | 1,244 | 300–2,000 |
| CD45RA+CCR7+ (%) | 78.5 | 57.4–84.9 | ||||
| CD45RA−CCR7+ (%) | 9.8 | 11.3–26.7 | ||||
| CD45RA−CCR7− (%) | 9.1 | 3.3–15.2 | ||||
| CD45RA+CCR7− (%) | 1.7 | 0.4–2.6 | ||||
| CD8+ T cells (cells/μl) | 1,570 | 400–2,300 | 1,009 | 300–1,600 | 1,459 | 300–1,800 |
| CD45RA+CCR7+ (%) | 44.9 | 28.4–80.6 | ||||
| CD45RA−CCR7+ (%) | 1 | 1–4.5 | ||||
| CD45RA−CCR7− (%) | 6.7 | 6.2–29.3 | ||||
| CD45RA+CCR7− (%) | 43.1 | 9.1–49.1 | ||||
| CD4/CD8 | 1.9 | 1–3 | 1.7 | 1–2.1 | 0.85 | 0.9–2.6 |
| CD56+CD16+ NK cells (cells/μl) | 110 | 61–510 | 99 | 70–590 | 231 | 70–590 |
| CD19+ B cells (cells/μl) | 1,560 | 529–1,930 | 1,532 | 323–1,000 | 788 | 212–796 |
| CD27−IgD+ naive (%) | 96 | 70–86 | 93 | 63–89 | ||
| CD27+IgD+ nonswitched memory (%) | 3 | 7–15 | 3 | 3–19 | ||
| CD27+IgD− class-switched memory (%) | 1 | 4–16 | 3 | 4–17 | ||
Abnormal results are shown in bold.